FY2024 Earnings Forecast for RGLS Issued By HC Wainwright

Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Regulus Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.86) per share for the year, down from their previous estimate of ($0.80). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Regulus Therapeutics' current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Regulus Therapeutics' Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

Other equities analysts also recently issued research reports about the company. Oppenheimer reissued an "outperform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock traded up $0.03 during mid-day trading on Thursday, hitting $1.53. The company's stock had a trading volume of 90,851 shares, compared to its average volume of 1,254,102. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company has a 50 day moving average of $1.55 and a 200-day moving average of $1.81. The stock has a market cap of $99.89 million, a PE ratio of -1.40 and a beta of 1.63.

Institutional Investors Weigh In On Regulus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Planning acquired a new position in shares of Regulus Therapeutics in the third quarter valued at about $26,000. SG Americas Securities LLC acquired a new position in shares of Regulus Therapeutics in the third quarter valued at about $33,000. Victory Capital Management Inc. increased its holdings in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after purchasing an additional 37,480 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company's stock valued at $211,000 after purchasing an additional 42,600 shares during the period. Finally, Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics in the second quarter valued at about $136,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.